Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB.B)
Mexico · Delayed Price · Currency is MXN 14.52
+0.11 (0.76%)
At close: Jul 22, 2026
Genomma Lab Internacional Income Statement
Financials in millions MXN. Fiscal year is January - December.
Millions MXN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17,046 | 17,541 | 18,607 | 16,467 | 16,820 | 15,487 | |
Revenue Growth (YoY) | -9.53% | -5.73% | 12.99% | -2.10% | 8.61% | 11.66% |
Cost of Revenue | 6,264 | 6,519 | 6,676 | 6,384 | 6,656 | 5,924 |
Gross Profit | 10,782 | 11,022 | 11,931 | 10,083 | 10,164 | 9,563 |
Selling, General & Admin | 7,275 | 7,292 | 8,055 | 6,889 | 6,922 | 6,570 |
Other Operating Expenses | -11.97 | -34.51 | -37.44 | -12.65 | -2.29 | -63.44 |
Operating Expenses | 7,257 | 7,258 | 8,018 | 6,876 | 6,920 | 6,507 |
Operating Income | 3,525 | 3,765 | 3,913 | 3,207 | 3,244 | 3,056 |
Interest Expense | -736.77 | -796.7 | -887.8 | -829.9 | -525.64 | -444.39 |
Interest & Investment Income | 114.02 | 114.02 | 106.11 | 156.93 | 118.05 | 65.43 |
Earnings From Equity Investments | - | - | - | - | - | -90.38 |
Currency Exchange Gain (Loss) | -199.03 | -392.05 | 113.58 | -543.51 | -208.75 | -25.92 |
Other Non Operating Income (Expenses) | -343.77 | -251.28 | -363.29 | -264.05 | -394.78 | -329.42 |
EBT Excluding Unusual Items | 2,359 | 2,439 | 2,882 | 1,727 | 2,232 | 2,232 |
Asset Writedown | - | - | - | -8.07 | -17.57 | -5.52 |
Other Unusual Items | -4.87 | -4.87 | 9.04 | 2.1 | 19.21 | -4.26 |
Pretax Income | 2,355 | 2,434 | 2,891 | 1,721 | 2,234 | 2,222 |
Income Tax Expense | 725.13 | 819.75 | 799.98 | 635.67 | 867.61 | 914.01 |
Earnings From Continuing Operations | 1,629 | 1,614 | 2,091 | 1,085 | 1,366 | 1,308 |
Earnings From Discontinued Operations | - | - | -597.99 | -58.6 | - | - |
Net Income to Company | 1,629 | 1,614 | 1,493 | 1,026 | 1,366 | 1,308 |
Net Income | 1,629 | 1,614 | 1,493 | 1,026 | 1,366 | 1,308 |
Net Income to Common | 1,629 | 1,614 | 1,493 | 1,026 | 1,366 | 1,308 |
Net Income Growth | -16.05% | 8.10% | 45.48% | -24.89% | 4.48% | -6.81% |
Shares Outstanding (Basic) | 975 | 976 | 978 | 957 | 993 | 1,008 |
Shares Outstanding (Diluted) | 975 | 976 | 978 | 957 | 993 | 1,008 |
Shares Change (YoY) | -2.48% | -0.23% | 2.20% | -3.61% | -1.43% | -0.41% |
EPS (Basic) | 1.67 | 1.65 | 1.53 | 1.07 | 1.38 | 1.30 |
EPS (Diluted) | 1.67 | 1.65 | 1.53 | 1.07 | 1.38 | 1.30 |
EPS Growth | -13.92% | 8.34% | 42.35% | -22.08% | 5.99% | -6.43% |
Free Cash Flow | 1,379 | 1,507 | 2,763 | 2,009 | 1,652 | 838.14 |
Free Cash Flow Per Share | 1.41 | 1.54 | 2.82 | 2.10 | 1.66 | 0.83 |
Dividend Per Share | 0.400 | 0.800 | 0.800 | 0.784 | 0.382 | 0.382 |
Dividend Growth | -66.67% | - | 2.00% | 105.49% | - | - |
Gross Margin | 63.25% | 62.84% | 64.12% | 61.23% | 60.43% | 61.75% |
Operating Margin | 20.68% | 21.46% | 21.03% | 19.48% | 19.28% | 19.73% |
Profit Margin | 9.56% | 9.20% | 8.03% | 6.23% | 8.12% | 8.45% |
Free Cash Flow Margin | 8.09% | 8.59% | 14.85% | 12.20% | 9.82% | 5.41% |
EBITDA | 3,896 | 4,144 | 4,273 | 3,434 | 3,471 | 3,227 |
EBITDA Margin | 22.86% | 23.62% | 22.96% | 20.86% | 20.63% | 20.83% |
D&A For EBITDA | 371.17 | 379.14 | 359.59 | 227.3 | 227.13 | 170.27 |
EBIT | 3,525 | 3,765 | 3,913 | 3,207 | 3,244 | 3,056 |
EBIT Margin | 20.68% | 21.46% | 21.03% | 19.48% | 19.28% | 19.73% |
Effective Tax Rate | 30.80% | 33.68% | 27.67% | 36.95% | 38.84% | 41.14% |